MedTrace Logo

A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

NCT06596642 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2025-06-04

No results posted yet for this study

Summary

This real-world study will assess the efficacy and safety of luspatercept treatment for β-thalassemia major in Taiwan as well as the impact on quality of life.

Conditions

  • β-Thalassemia Major

Interventions

DRUG

Luspatercept

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-21
Primary Completion
2026-10-01
Completion
2026-12-17
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06596642 on ClinicalTrials.gov